GlassScriptPhysician profile
Angela Birdwell
NPI 1043621030
$3,608.15
in general payments reported to CMS, 2019-2025
15 companies · $93.47 in 2025
The $93.47 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $21.64 · 2022: $37.66 · 2023: $42.35 · 2024: $2,521 · 2025: $93.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Charitable Contribution: $2,500 · Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Charitable Contribution | $2,500.00 |
| Food and Beverage | $157.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,500.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.69 | 2019-2025 | |
| Insmed, INC. | $220.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $133.20 | 2019 | |
| Alexion Pharmaceuticals, INC. | $122.07 | 2019 | |
| Merck Sharp & Dohme LLC | $65.35 | 2019-2025 | Zerbaxa |
| Abbvie INC. | $42.35 | 2023 | Avycaz |
| Janssen Pharmaceuticals, INC | $37.66 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $31.75 | 2025 | Dupixent |
| Amgen INC. | $21.35 | 2024 | Tezspire |
| Tactile Systems Technology INC | $21.12 | 2025 | Flexitouch Plus, Nimbl |
| Electromed, INC. | $19.52 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.24 | 2019 | |
| Genentech USA, INC. | $15.64 | 2019 | |
| Melinta Therapeutics, LLC | $14.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Birdwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.